Title |
sLAG-3 in non-small-cell lung cancer patients’ serum
|
---|---|
Published in |
OncoTargets and therapy, August 2018
|
DOI | 10.2147/ott.s164178 |
Pubmed ID | |
Authors |
Yayi He, Yan Wang, Sha Zhao, Chao Zhao, Caicun Zhou, Fred R Hirsch |
Abstract |
Anti-programmed cell death-1/programmed cell death ligand-1 monoclonal antibodies have been widely used in non-small-cell lung cancer (NSCLC), but not every patient can get benefits from them. Whether other molecular markers can predict the results of programmed cell death-1/programmed cell death ligand-1 inhibitors need to be explored. Lymphocyte-activation gene-3 (LAG-3) is another important immune checkpoint, which can inhibit tumor immunity. Soluble LAG-3 (sLAG-3) plays different functions from LAG-3. In this study, we detected the serum sLAG-3 level in NSCLC patients. sLAG-3 was detected in 247 hospitalized patients by enzyme-linked immunosorbent assay. Every sample was repeated three times. Two-hundred forty-seven hospitalized patients were enrolled in this study. Of them, 71 had benign diseases and 176 were NSCLC patients. sLAG-3 in NSCLC serum was correlated with NSCLC stage. The sLAG-3 levels were significantly higher in stage I-II NSCLC than in stage III-IV (p<0.001). The advanced NSCLC had the lower sLAG-3 expression. This might be related to the poor cancer immune response. Increasing sLAG-3 level might be a promising treatment in advanced NSCLC patients. |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 20 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Master | 5 | 25% |
Other | 2 | 10% |
Student > Bachelor | 2 | 10% |
Student > Ph. D. Student | 2 | 10% |
Student > Doctoral Student | 1 | 5% |
Other | 2 | 10% |
Unknown | 6 | 30% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 7 | 35% |
Biochemistry, Genetics and Molecular Biology | 2 | 10% |
Immunology and Microbiology | 2 | 10% |
Agricultural and Biological Sciences | 1 | 5% |
Unknown | 8 | 40% |